SAN DIEGO and BRUSSELS–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, and the European Organisation for Research and Treatment of Cancer (EORTC) today announced that they will collaborate via EORTC’s Screening Patients for Efficient Clinical Trial Access (SPECTA) biomarker screening initiative to identify patients who harbor a gene rearrangement to NTRK1, NTRK3, ROS1… Read more »
Cambridge, UK: 16 November 2015. 14M Genomics (“14MG”) and The European Organisation for Research and Treatment of Cancer (“EORTC”) today announce the delivery of initial genomic mutation analyses conducted on newly diagnosed cancer patients as part of the EORTC Screening Patients for Efficient Clinical Trial Access (SPECTA) programme. The first SPECTA project, SPECTAcolor, focuses on… Read more »
On 22 October 2015, the SPECTAcolor project investigators met up at the occasion of the bi-annual series of SPECTAcolor Steering Committee meetings to discuss the Biobank project progress. This private meeting was held concurrently with the EORTC GITCG semi annual meeting in Antwerp, Belgium. View the agenda of the investigators’ meeting for information. … Read more »
SPECTAcolor is the first ever tumour tissue samples biobank and biomarker analysis platform for genetic profiling of patients suffering from advanced colorectal cancer. This platform, unique of its kind joins up research clinical forces at a Pan-European level to develop personalized treatments based on the results of the tissue sampling analysis. Supported by a network of over… Read more »
Read what EORTC Director General Denis Lacombe has to say about the scientific complexity and economic cost of developing new cancer therapies, which demand a level of collaboration and sharing that takes both industry and academia well beyond their comfort zones, in the September-October issue of Cancer World.
Barcelona – The Catalan Institute of Oncology (ICO) today welcomed a party of over 35 delegates from Walgreens Boots Alliance, the first global pharmacy-led health and wellbeing enterprise to showcase the workings of the Screening Patients for Efficient Clinical Trial Access (SPECTAcolor) Biobank of the European Organisation for Research and Treatment of Cancer (EORTC)… Read more »
Over 500 patients in and availability of high quality biological materials SPECTAcolor’s successful start has demonstrated its viability to facilitate next generation cancer clinical trials. It has been successfully implemented across 21 clinical centers located in nine countries in Europe, has now recruited over 500 patients since its launch in September 2013, and the observed frequency… Read more »
Hear EORTC Medical Director Dr Vassilis Golfinopoulos talk about the aims of SPECTA (Screening Patients for Efficient Clinical Trial Access) and catch up on other news from 26th EORTC – NCI – AACR symposium on molecular targets in cancer therapeutics in Barcelona.
On 19 November 2014, the SPECTAcolor project investigators and partners met up at the occasion of the 2nd of the bi-annual series of SPECTAcolor Steering Committee Meetings to discuss the biobank project progress. View the agenda of the investigators’ meeting for information. This private meeting is to be traditionally held concurrently at the occasion of the GI Oncology Study… Read more »
The EORTC is pleased to announce the successful implementation of SPECTAcolor, ‘Screening Patients for Efficient Clinical Trial Access’ – the first Pan European collaborative molecular screening platform for colorectal cancer patients. SPECTAcolor proves the logistical feasibility of the infrastructure that was built to run next generation trials in a multinational setting. Now one year into… Read more »
Walgreens Boots Alliance is supporting SPECTAcolor through fundraising.